Why NeuroPace Stock Was Inching Higher on Wednesday

By Eric Volkman – Mar 4, 2026 at 3:24PM ESTKey PointsThe niche medical devices specialist published its latest quarterly and annual fundamentals.Led by its No. 1 product, it posted a double-digit revenue gain and narrowed its net loss in the fourth quarter.Medical device company NeuroPace (NPCE +1.37%) was showing signs of life on the stock market Wednesday. In late-session trading, the company's shares were slightly in positive territory with a nearly 1% rise. This was largely a reaction to its latest earnings release, published after market close on Tuesday. Outpacing expectations That release covered NeuroPace's fourth-quarter and full-year 2025 performance; in the fourth quarter, the company reported revenue of $26.6 million. That was a robust (24%) improvement over the same quarter of 2024. The medical device specialist also managed to narrow its net loss under generally accepted accounting principles (GAAP) to $2.7 million ($0.08 per share) from the year-ago deficit of almost $5.3 million. Image source: Getty Images. That meant a double beat for NeuroPace, as the consensus analyst estimate for revenue was $24.4 million and for net loss per share was $0.18. In its earnings release, NeuroPace attributed its growth to favorable Medicare reimbursement decisions and increases in prescribers and accounts. Overall, its main revenue driver -- the RNS System, an epilepsy treatment device -- saw sales rise 26% to over $22 million. ExpandNASDAQ: NPCENeuroPaceToday's Change(1.37%) $0.19Current Price$14.02Key Data PointsMarket Cap$461MDay's Range$13.19 - $15.7052wk Range$7.56 - $18.98Volume23KAvg Vol202KGross Margin76.77% A unique product Management reiterated its full-year 2026 guidance of $98 million to $100 million for revenue, and a non-GAAP (adjusted) earnings before interest, taxes, depreciation, and amortization (EBITDA) loss of $9 million to $10 million. By comparison, the 2025 figures were $100 million and $5 million, respectively. Compared to the quarter's growth, that guidance wasn't all that impressive (a likely reason for the muted investor reaction). Still, NeuroPace clearly has a unique, winning product in the RNS System, and I think the stock has good potential on that basis alone.Read NextJul 3, 2021 •By Patrick BafumaCould This Recently IPOed Medical Device Maker Make You Rich?About the AuthorEric Volkman is a contributing Motley Fool finance and stock market analyst. Previously, Eric was an equities analyst at European investment bank Raiffeisen Capital and Investment. He’s also been a freelance finance writer since 1995. He studied at Susquehanna University.TMFVolkmanStocks MentionedNeuroPaceNASDAQ: NPCE$14.02(+1.37%)+$0.19*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.